Poseida Therapeutics Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Poseida Therapeutics Inc 's ROA in the third quarter of 2024?
Poseida Therapeutics Inc recorded a cumulative net loss of $-61 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -23.08%.

However, within the Healthcare sector 386 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2024 quarter, so far to 3733, from total ROA ranking in the second quarter of 2024 at 4126.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Total Assets Change	-2.12 %	8.46 %	-16.09 %	-22.77 %	-20.55 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-61	-113	-109	-123	-132
Return On Assets (TTM)	-23.08 %	-42.6 %	-41.99 %	-45.56 %	-45.58 %
PSTX's Total Ranking	# 3733	# 4126	# 4177	# 4874	# 4352
Total Assets (TTM) in million	276	281	244	253	282
Seq. Total Assets Change	-1.79 %	15.19 %	-3.73 %	-10.13 %	8.83 %
Seq. Net Income Change	-	-	-	-	-

PSTX's 5 Years Annual ROA >> Back to PSTX Management Effectiveness >> Compare PSTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 41
Sector	# 387
Overall	# 3664

Return On Assets Statistics
High	Average	Low
-8.99 %	-36.05 %	-57.69 %
(Jun 30 2023)		(Jun 30 2022)

Financial Statements
Poseida Therapeutics Inc 's Assets	$ 276 million	PSTX's Balance sheet
Poseida Therapeutics Inc 's Income	$ 20 million	Quarterly PSTX's Income Statement
PSTX's Income by Division		See PSTX's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	FY
Y / Y Total Assets Change	-22.77 %	34.04 %	-70.85 %	-	-
Total Assets in million	253	328	244	839	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-123	-64	-125	-130	0
Annual Return On Assets	-48.77 %	-19.53 %	-51.12 %	-15.47 %	-

PSTX's 5 Years Annual ROA >> Back to PSTX Management Effectiveness >> Compare PSTX ROA to its Competitors

More Return On Assets Ratios
PSTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PSTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PSTX's Competitors
Subscribers only: Roa for Poseida Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PSTX's Customers

You may also want to know
PSTX's Roi	PSTX's Inventory Turnover Ratio	PSTX's Growth Rates	PSTX's Dividend Comparisons
	PSTX's Profitability Ratios	PSTX's Asset Turnover Ratio	PSTX's Dividend Growth
PSTX's Roe	PSTX's Valuation Ratios	PSTX's Financial Strength Ratios	PSTX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.